NASDAQ · VTRS
Healthcare · Drug Manufacturers - Specialty & Generic
$16.17
Down-$0.06 (-0.37%)
Updated Aug 19, 2026, 4:21 AM
SID Score
7.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
VTRS closed at $16.17 after 21 trading sessions, down 8.07% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $16.36 | $16.52 | $16.165 | $16.17 | 9.05M |
| Aug 17, 2026 | $16.12 | $16.30 | $16.09 | $16.23 | 7.89M |
| Aug 14, 2026 | $15.902 | $16.27 | $15.88 | $16.23 | 8.2M |
| Aug 13, 2026 | $16.28 | $16.38 | $15.99 | $16.04 | 16.16M |
| Aug 12, 2026 | $16.16 | $16.34 | $15.98 | $16.10 | 13.61M |
| Aug 11, 2026 | $16.26 | $16.565 | $16.135 | $16.28 | 12.76M |
| Aug 10, 2026 | $16.302 | $16.71 | $16.13 | $16.28 | 13.23M |
| Aug 7, 2026 | $16.48 | $16.78 | $16.20 | $16.43 | 13.02M |
| Aug 6, 2026 | $18.15 | $18.39 | $16.22 | $16.29 | 21.02M |
| Aug 5, 2026 | $17.80 | $17.88 | $17.55 | $17.65 | 11.35M |
| Aug 4, 2026 | $17.66 | $17.75 | $17.37 | $17.70 | 8.89M |
| Aug 3, 2026 | $17.74 | $17.76 | $17.31 | $17.63 | 8.8M |
| Jul 31, 2026 | $17.65 | $17.69 | $17.375 | $17.56 | 15.57M |
| Jul 30, 2026 | $17.63 | $17.79 | $17.50 | $17.76 | 5.8M |
| Jul 29, 2026 | $17.955 | $18.07 | $17.67 | $17.82 | 10.03M |
| Jul 28, 2026 | $17.75 | $17.94 | $17.64 | $17.86 | 9.6M |
| Jul 27, 2026 | $17.35 | $17.75 | $17.28 | $17.635 | 9.76M |
| Jul 24, 2026 | $17.28 | $17.4888 | $17.195 | $17.24 | 7.37M |
| Jul 23, 2026 | $16.875 | $17.28 | $16.755 | $17.28 | 7.91M |
| Jul 22, 2026 | $17.57 | $17.57 | $16.90 | $17.01 | 14.63M |
| Jul 21, 2026 | $16.96 | $17.675 | $16.83 | $17.59 | 8.55M |
The latest Smart Investors Daily articles mentioning VTRS.
VTRS research
Company profile and research snapshot.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2026 | Barclays | Overweight | — |
| May 8, 2026 | Truist Securities | Buy | — |
| May 8, 2026 | JP Morgan | Neutral | — |
| Mar 24, 2026 | Barclays | Overweight | — |
| Jan 28, 2026 | Piper Sandler | Neutral | — |
No generated briefing is available yet.
Yahoo · Aug 13, 2026
According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent […]
Yahoo · Aug 13, 2026
Greater China surges 16% as management raises full-year guidance.
Yahoo · Aug 12, 2026
Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
Yahoo · Aug 11, 2026
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VTRS.
